DDInter1300 DDInter1658
Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Nitisinone {u} (Compound) resembles {v} (Compound) Flutamide
Nitisinone {u} (Compound) resembles {v} (Compound) Nilutamide
Nitisinone {u} (Compound) binds {v} (Gene) HPD
Nitisinone {u} (Compound) is included by {v} (Pharmacologic Class) Hydroxyphenylpyruvate Dioxygenase Inhibitors
Nitisinone {u} (Compound) causes {v} (Side Effect) Rash erythematous
Nitisinone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Netupitant
Nitisinone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Butalbital
Nitisinone (Compound) resembles Flutamide (Compound)
Nitisinone (Compound) resembles Nilutamide (Compound)
Nitisinone (Compound) binds HPD (Gene)
Nitisinone (Compound) is included by Hydroxyphenylpyruvate Dioxygenase Inhibitors (Pharmacologic Class)
Nitisinone (Compound) causes Rash erythematous (Side Effect)
Nitisinone may cause a minor interaction that can limit clinical effects when taken with Modafinil
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Netupitant
Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Butalbital